Compare LESL & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LESL | HOTH |
|---|---|---|
| Founded | 1963 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.7M | 16.6M |
| IPO Year | 2020 | 2019 |
| Metric | LESL | HOTH |
|---|---|---|
| Price | $1.14 | $1.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 1 |
| Target Price | ★ $14.97 | $5.00 |
| AVG Volume (30 Days) | 121.7K | ★ 855.2K |
| Earning Date | 02-17-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,241,915,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.27 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.12 | $0.66 |
| 52 Week High | $34.90 | $2.12 |
| Indicator | LESL | HOTH |
|---|---|---|
| Relative Strength Index (RSI) | 33.87 | 57.05 |
| Support Level | $1.19 | $0.77 |
| Resistance Level | $1.46 | $0.97 |
| Average True Range (ATR) | 0.13 | 0.08 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 0.61 | 97.35 |
Leslies Inc is a direct-to-consumer pool and spa care brand offering a comprehensive assortment of products, including chemicals, equipment and parts, cleaning and maintenance equipment, and safety, recreational, and fitness-related products. The company serves residential pool, residential spa, professional pool, and commercial pool consumers and markets its products through over 1,000 company-operated locations in 39 states and e-commerce websites, operating only in the United States. It operates mainly in the pool and spa aftermarket industry and offers regularly purchased, non-discretionary maintenance items, along with installation and repair services for pool and spa equipment.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).